0000000000677172
AUTHOR
Magdalena Corona
SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders
Abstract Background The clinical efficacy of SARS-CoV-2 vaccines according to antibody response in immunosuppressed patients such as hematological patients has not yet been established. Patients and methods A prospective multicenter registry-based cohort study conducted from December 2020 to December 2021 by the Spanish transplant and cell therapy group was used to analyze the relationship of antibody response at 3–6 weeks after full vaccination (2 doses) with breakthrough SARS-CoV-2 infection in 1394 patients with hematological disorders. Results At a median follow-up of 165 days after complete immunization, 37 out of 1394 (2.6%) developed breakthrough SARS-CoV-2 infection at median of 77 …
Additional file 1 of SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders
Additional file 1: Table S1. Characteristics of serological assays used in the study. Table S2. Commercial PCR test available in participating centers.